His week begins with blood. Every Monday, Dr. Siddhartha Mukherjee arrives early at his Columbia University lab to stare through the microscope at slides of red. Waiting very much in Shakespearean fashion for his patient's blood to speak to him.
We speak on a Thursday. Mukherjee is in his loft in New York, making a sandwich and promoting his new book The Song of The Cell: An Exploration of Medicine and The New Human. It is his fourth book, the earlier ones being The Emperor of All Maladies: A Biography of Cancer (which won him a Pulitzer), The Laws of Medicine: Field Notes from an Uncertain Science and The Gene: An Intimate History. Its arrival in stores is very much a worldwide publishing event.
The next two months are big for Mukherjee, for his various identities of oncologist, scientist, writer, and now entrepreneur. Book aside, in December, he flies to Bengaluru to assess the results of a CAR (chimeric antigen receptor) T cell trial for cancer. His laboratory, which has a reputation for cancer research, is responsible for starting one of India's first clinical trials of T-cell therapy.
AT cell is a kind of white blood cell. "A CAR T cell is a T cell that has been weaponised against cancer," he says. "It is a process that can be highly effective in curing patients, but it is also very dangerous."
Immuneel Therapeutics, the Bengaluru-based company that Mukherjee and Biocon chief Kiran Mazumdar Shaw started, is working towards a treatment that will cost far less than treatments in the US. It has recently raised $15 million. IIT Bombay and Tata Memorial are also doing similar trials; theirs is in phase one, and Immuneel is in phase two.
Diese Geschichte stammt aus der November 06, 2022-Ausgabe von THE WEEK India.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der November 06, 2022-Ausgabe von THE WEEK India.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
What Will It Take To Clean Up Delhi Air?
IT IS ASKED, year after year, why Delhi’s air remains unbreathable despite several interventions to reduce pollution.
Trump and the crisis of liberalism
Although Donald Trump's election to a non-consecutive second term to the US presidency is not unprecedented—Grover Cleveland had done it in 1893—it is nevertheless a watershed moment.
Men eye the woman's purse
A couple of months ago, I chanced upon a young 20-something man at my gym walking out with a women’s sling bag.
When trees hold hands
A filmmaker explores the human-nature connect through the living root bridges
Ms Gee & Gen Z
The vibrant Anuja Chauhan and her daughter Nayantara on the generational gap in romance writing
Vikram Seth-a suitable man
Our golden boy of literature was the star attraction at the recent Shillong Literary Festival in mysterious Meghalaya.
Superman bites the dust
When my granddaughter Kim was about three, I often took her to play in a nearby park.
OLD MAN AND THE SEA
Meet G. Govinda Menon, the 102-year-old engineer who had a key role in surveying the Vizhinjam coast in the 1940s, assessing its potential for an international port
Managing volatility: smarter equity choices in uncertain markets
THE INDIAN STOCK MARKET has delivered a strong 11 per cent CAGR over the past decade, with positive returns for eight straight years.
Investing in actively managed low-volatility portfolios keeps risks at bay
AFTER A ROARING bull market over the past year, equity markets in the recent months have gone into a correction mode as FIIs go on a selling spree. Volatility has risen and investment returns are hurt.
